Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Ho, Ping-Chih

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. [electronic resource] - Cancer research Jun 2014 - 3205-17 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural

1538-7445

10.1158/0008-5472.CAN-13-3461 doi


Animals
Antigen-Presenting Cells--drug effects
Antineoplastic Agents--pharmacology
CD4-Positive T-Lymphocytes--drug effects
CD40 Ligand--physiology
Drug Screening Assays, Antitumor
Indoles--pharmacology
Interferon-gamma--physiology
Macrophages--drug effects
Melanoma, Experimental--drug therapy
Mice
Mice, Transgenic
Mutation, Missense
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Signal Transduction
Skin Neoplasms--drug therapy
Sulfonamides--pharmacology
Tumor Microenvironment--immunology